ICON Releases NONMEM 7.2
ICON
announced the release of a new version of NONMEM, ICON’s non-linear, mixed effects modeling tool for Population Pharmacokinetic/Pharmacodynamic (PK/PD) data analysis.
One year following the release of NONMEM® 7, which included a new suite of statistical methods to support more complex models for analysing Population PK/PD data and a more comprehensive range of classical estimation methods, ICON has released NONMEM® 7.2, which includes the following enhancements:
- Parallel computing of a single problem over multiple cores or computers, significantly reducing completion time.
- Dynamic memory allocation according to problem size, eliminating the need to recompile the NONMEM® program for unusually large problems. User may override program generated suggested values using a statement in the control stream.
- Other improvements include control stream files that may be written in mixed case, added flexibility in the input and output of variance matrix parameters, XML markup version of the NONMEM® report file, as well as features to facilitate stochastic differential equations (SDE).
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
